Alchemab Therapeutics is an exciting, big ambition, fast-paced antibody therapeutics company. The company brings together cutting-edge technologies including antibody repertoire profiling, deep learning and PhIP-Seq (Phage Immunoprecipitation Sequencing) proteomic analysis and world-leading expert Founders and management team. Alchemab is initially focused on the areas of oncology, neuroscience and infectious disease.
Currently at Series A stage, Alchemab aims to deliver a pipeline of targets and therapeutic candidates over the next 18 months. Beyond this, Alchemab aims to be a transformational large molecule therapeutics company with a broad pipeline of internal and partnered novel targets & candidates. The company has its headquarters in London, but with research activity primarily in Cambridge.